Each year, approximately 32,000 new patients are diagnosed with pancreatic cancer (PC) in the US. The incidence has been increasing since the 1930s. Prognosis of PC is extremely poor. Approximately 31,000 patients in the US die from PC each year, making it the fourth leading cause of cancer-related death in the US.
p=0.099). 5 This study was also criticized for suboptimal XRT-lower doses and split courses-that may have allowed cancer repopulation between courses, thereby underestimating the benefit of CRT.
The trial ESPAC-1 was a two-by-two factorial designed study comparing adjuvant concurrent CRT (bolus 5-FU/split-course radiation), chemotherapy alone (5-FU/Leucovorin (LV)), CRT followed by chemotherapy, and observation. The chemotherapy-only arm had statistically significant benefit over the observation arm in MS (20.1 versus 15.5 months; p=0.009).
However, the CRT arm showed worse MS (15.9 versus 17.9 months; p=0.05). 6 The RTOG 9704 study randomized 538 resected PC patients to evaluate the benefit of adding gemcitabine to infusional 5-FU combined with XRT (5- 
difference when pancreatic body and tail cancers were all included, patients with pancreatic head tumors (n=380) showed benefit in MS (18.8 versus 16.7 months; p=0.047). 7 While the benefit of XRT was inconclusive in randomized trials (see Table 1 
Chemotherapy Alone
In the CONKO-001 study, Oettle et al. randomized 368 patients with resected PC to gemcitabine or observation for six months. Tumor prognostic characteristics were similar in both arms. This trial showed a statistically significant disease-free survival (DFS) benefit (13.4 versus 6.9 months; p<0.001) of gemcitabine over observation (see Table 1 ). Treatment with gemcitabine caused a trend toward OS benefit (22.1 versus 20.2 months; p=0.06). 10 This benefit of chemotherapy was consistent with the result from the ESPAC-1 trial, which showed the benefit of 5-FU/LV over no adjuvant therapy in PC patients (MS 19.7 versus 14 months) who had complete resection. 6 The role of gemcitabine as a single agent will further be defined by the ongoing ESPAC-3 study, which is a randomized phase III study comparing observation versus 5-FU versus gemcitabine in the adjuvant setting of PC.
Locally Advanced Pancreatic Cancer
Approximately 30% of patients have locally advanced disease at the time of diagnosis with MS of six to 10 months. 11 PCs are deemed unresectable when the following features are present:
• involvement of superior mesenteric artery or celiac axis;
• absence of vascular flow through the superior mesenteric vein-portal vein (SMV-PV) confluence;
• complete encasement of SMV-PV confluence leading to vascular thrombosis and cessation of blood flow in the SMV-PV;
• celiac axis involvement/encasement with tumor or direct involvement of inferior vena cava or aorta;
• extrapancreatic involvement; or
• distant metastases.
Combined Modality with Chemoradiation Therapy (see Table 2 ) 12 This result was supported by GITSG when they reported a significant survival benefit (one-year survival rate 40 versus 10%) of 5-FU-based CRT over radiation only. 13 In the US, commonly accepted practice is to use 14,15
5-FU-based Chemoradiation Therapy

Gemcitabine-based Chemoradiation Therapy
Gemcitabine-based CRT has been investigated since the benefit of gemcitabine over 5-FU in APC was reported. Optimal administration strategies for this regimen are still being investigated in clinical-trial settings.
Due to high toxicity with this regimen in early trials, the Cancer and Leukemia Group B (CALGB) conducted a phase II trial of concurrent XRT (50.4Gy) and low-dose weekly gemcitabine (40mg/m 2 twice weekly) in patients with LAPC. This regimen rendered a disappointing median OS rate of 8.2 months. 16 However, in patients with an Eastern Co-operative Oncology Group (ECOG) performance status score of zero, MS was 13.7 months. The
Hoosier Oncology Group (HOG) treated patients with LAPC with weekly gemcitabine (600mg/m 2 ) with concurrent XRT (50.4Gy) followed by gemcitabine monotherapy. This regimen showed more favorable side-effect profiles along with a promising one-year survival rate of 31.1%.
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Paclitaxel-based Chemoradiation Therapy
Paclitaxel has shown activity against LAPC in combination with XRT. The
Brown University Oncology Group reported a 26% response rate in 42 patients with LAPC. 18 A phase II trial with the combination weekly paclitaxel plus XRT has been conducted (RTOG 9812) and data are maturing. 19 Newer technologies in XRT, including three-dimensional conformal RT, which allows reduction of radiation fields and optimization of radiation-sensitizing chemotherapy, will improve treatment of LAPC in the future.
Is the Therapeutic Index Better with Gemcitabine Radiation
Therapy than with 5-FU Radiation Therapy?
A review of the literature suggests significantly higher severe toxicity rates with gemcitabine than with 5-FU when used as a radiosensitizer in LAPC.
Median and one-year survivals were not significantly different with the use Gemcitabine+XRT
One-year survival rate of 31.1% followed by gemcitabine Safran et al. 18 Paclitaxel+XRT
Response rate of 26% Saif et al. 14 
Capecitabine+XRT
Response rate of 20% followed by capecitabine MS of 14 months XRT = radiation therapy. 
Advanced Pancreatic Cancer
Up to 60% of patients have metastatic disease at the time of diagnosis. The MS rates of these patients are dismal at between three and six months. 2 After the approval of gemcitabine in 1997 (see Table 3 
Cytotoxic Agents
Gemcitabine
Gemcitabine has been compared with 5-FU in APC patients and showed its superiority in clinical response rates (24 versus 5%) and one-year survival rates (18 versus 2%) in a randomized study by Burris HA et al. 21 (see Table   3 ). In addition to the survival benefit, gemcitabine was also superior to 5-FU in producing clinical benefit response (see Figure 1 ). This study led to the approval of gemcitabine as a first-line chemotherapy agent. 21 
Fixed Dose Rate versus Conventional 30-minute
Infusion of Gemcitabine
The benefit of fixed dose rate (FDR) gemcitabine versus the standard 30-minute infusion schedule, which was proposed in a phase II trial, was contradicted by a US intergroup randomized phase III trial (ECOG-6201), which showed no difference between the two schedules. 22 Increased myelosuppression is associated with FDR gemcitabine infusion (neutropenia, thrombocytopenia).
Gemcitabine versus Gemcitabine/Platinum
Gemcitabine/oxaliplatin (GEMOX) showed encouraging results in a phase II trial and led to randomized trials comparing GEMOX with gemcitabine months; p=0.04) than that of gemcitabine. GEMOX also rendered better response rates (27 versus 17%; p=0.04). There was a trend toward MS benefit (9 versus 7.1 months; p=0.13). Toxicities from both arms were acceptable, while GEMOX was more myelosuppressive and caused more peripheral neuropathies. 23 The major criticism for this study was that it compared a 30-minute infusion with an FDR infusion in GEMOX regimen.
The US intergroup trial ECOG 6201 compared standard 30-minute gemcitabine versus FDR gemcitabine versus GEMOX. Preliminary data from 2006 failed to show significant advantages of GEMOX to gemcitabine monotherapy. 22 Other gemcitabine/platinum combinations gave rise to benefits. A gemcitabine and cisplatin combination showed significant improvement against disease progression and in response rates.
Heinemann et al. also showed 2.2 months' prolongation of PFS (p=0.53)
by the addition of cisplatin to gemcitabine. 24 
Gemcitabine versus Gemcitabine + Fluoropyrimidines
While phase III randomized trials did not show any benefit of adding 5-FU p=0.008) and improved OS (HR: 0.80; p=0.026). The incidence of myelosuppression was higher in the combination arm, and hand-foot syndrome was noted only in the combination arm. 26 The final results of the study are anxiously awaited. Addition of S-1, a novel oral fluoropyrimidine derivative, to gemcitabine in patients with MPC showed promising activity in a phase II study of 54 patients. Response rates were 44% and MS was 10.1 months with an acceptable toxicity profile. A randomized phase III trial is being undertaken.
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Targeted Agents
Based upon the biology of PC, the following classes of targeted agents are being investigated actively: epidermal growth factor receptor (EGFR) inhibitors, vascular endothelial growth factor receptor (VEGFR) inhibitors, farnesyltransferase inhibitors, matrix metalloproteinase inhibitors, and cyclooxygenase-2 (COX-2) inhibitors.
Epidermal Growth Factor Receptor Inhibitors
The National Cancer Institute of Canada randomized patients with LAPC and MPC to gemcitabine/erlotinib and gemcitabine/placebo. The addition of erlotinib resulted in a statistically significant benefit in survival rate (HR: 0.81; 95% CI: 0.67-0.97; p=0.025). Improvement of MS was from 5.9 to 6.4 months, and one-year survival rate improved from 17 to 24%. 28 This study led to the approval of erlotinib by FDA-the first biologic plus gemcitabine combination that showed benefit after the efforts of a decade. A rash was the most common toxicity associated with erlotinib and correlated with the expected outcome.
Cetuximab, an anti-EGFR chimeric monoclonal antibody, in combination with gemcitabine showed promising activity in a phase II trial by Xiong et al. 29 Forty-one patients with LAPC and MPC were treated with this regimen and showed 12.2% relative risk (RR), median OS of 7.1 months, and oneyear OS of 31.7%. Cetuximab was dosed with 400mg/m 2 loading followed by a 250mg/m 2 weekly dose. Gemcitabine was given at 1000mg/m 2 on a schedule of seven weeks on and one week off. This regimen was well tolerated with the most common side effects being neutropenia (39%) and asthenia (22%). 29 In an effort to confirm this result, a phase III randomized trial is being conducted by the Southwest Oncology Group (SWOG). 30 The Preliminary results were presented at the Gastrointestinal Symposium in January 2007. The conclusion of this study was that the addition of bevacizumab to gemcitabine did not improve survival in MPC. 32 Of note is that more patients with ECOG performance status of zero were enrolled in the phase II study than in the phase III study, all patients had APC in the phase III study versus APC and LAPC in the phase II study, and 23% had received prior radiotherapy among phase II patients versus 11% in the phase III study.
A GEMOX plus bevacizumab combination in a phase II trial including 82 patients with MPC showed six-month survival of 68% (95% CI: 57.1-81.0) and MS of 9.4 months (95% CI: 7.2-11.0). 33 The combination of gemcitabine with sorafenib, a small-molecule multikinase inhibitor, was tested in a small phase II trial of patients with MPC. 33 Sorafenib was dosed at 400mg twice daily for 28 days along with gemcitabine 1000mg/m 2 on days one, eight, and 15 in a 28-day cycle. In this small study of 17 patients, the combination regimen was well tolerated but was inactive. Sorafenib, in addition to inhibiting VEGF, inhibits the raf-1 kinase and platelet-derived growth factor receptor (PDGFR) tyrosine kinase, and may have enhanced activities compared with bevacizumab, which only inhibits VEGF. A larger study has been proposed to investigate its activity.
Ras-farnesyltransferase Inhibitors and Matrix
Metalloproteinase Inhibitors
Ras-farnesyltransferase inhibitors and matrix metalloproteinase inhibitors were shown to be ineffective against MPC as single agents or in combination in various phase III trials. Studies combining targeted agents are being pursued in Europe and the US.
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Conclusions
Although we have made incremental progress in the treatment of PC, the prognosis of patients with this disease remains extremely poor. Gemcitabine plus erlotinib or capecitabine is considered the standard of care for APC patients in North America. In pilot studies of modern combination chemotherapy, responses may exceed those of single-agent gemcitabine, but with added toxicities. However, patients with LAPC seem to derive more benefit from combination chemotherapy than those with APC, and should be studied separately in future studies. The role of XRT in the adjuvant therapy remains split between the US and Europe. We definitely need to identify surrogates for survival. In addition, oncologists need to change their attitude toward clinical trials. The development of novel agents and approaches is urgently needed in conjunction with improvement in access to clinical trials for patients. ■
